Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.
Status:
Unknown status
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
This study aimed to investigate the efficacy and safety of pegylated liposomal doxorubicin
together with etoposide and methylprednisolone as a induction therapy for lymphoma induced
hemophagocytic lymphohistiocytosis.